Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1/PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-04

Study Completion Date

2021-06-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase I/II peptide receptor radiotherapy (PRRT) trial of 177Lu-DOTA-OCTREOTATE in children and adolescents with neuroendocrine tumors and pheochromocytoma or paraganglioma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

NCT03966651

Neuroblastoma

RECRUITING PHASE1

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

NCT00049023

Brain and Central Nervous System Tumors Gastrointestinal Carcinoid Tumor Islet Cell Tumor +4 more

COMPLETED PHASE1

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331

Somatostatin Receptor Positive NETs Lymphoma +5 more

RECRUITING PHASE1

Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors

NCT03234309

Brain Neoplasm

WITHDRAWN PHASE2

Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma

NCT00432445

Retinoblastoma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this clinical trial is to determine if peptide receptor radiotherapy (PRRT) using 177Lu-DOTA-OCTREOTATE given intravenously in children and adolescents is an effective treatment and to describe its toxicities.

This study will consists of children and adolescents ages 1-20 years with relapsed or refractory neuroendocrine tumors and pheochromocytoma or paraganglioma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuroendocrine Tumors Pheochromocytoma Paraganglioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRRT with 177Lu-DOTA-tyr3-OCTREOTATE

177Lu-DOTA-tyr3-OCTREOTATE (177Lu-DOTATATE) and amino acid will be administered intravenously (IV) on Day 1 of each of four treatment cycles, 8 weeks apart.

This study will consist of children and adolescents ages 1-20 years with relapsed or refractory neuroendocrine tumors and pheochromocytoma or paraganglioma. Children and adolescents with neuroendocrine tumor, pheochromocytoma or paraganglioma will not have had any previous endoradiotherapy with 90Y-DOTATOC, 131I-MIBG, or 177Lu-DOTATATE.

Group Type EXPERIMENTAL

177Lu-DOTA-tyr3-OCTREOTATE

Intervention Type DRUG

This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.

Peptide Receptor Radiotherapy (PRRT)

Intervention Type PROCEDURE

PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

177Lu-DOTA-tyr3-OCTREOTATE

This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.

Intervention Type DRUG

Peptide Receptor Radiotherapy (PRRT)

PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lutathera

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Disease not amenable to standard treatment (nonresectable or disease present after one or more surgeries and/or Sandostatin treatment) or subject has failed existing first line chemotherapy, biologic therapy, targeted agent therapy or radiation therapy.
* Participation in Iowa Neuroendocrine Tumor Registry and recommendation by University of Iowa PRRT tumor board.
* A pathologically confirmed (histology or cytology) Neuroendocrine Tumor (NET), Pheochromocytoma (PCC), or Paraganglioma (PGL).
* For patients with measurable or evaluable disease: \>50% of lesions must demonstrate 68Ga-DOTATATE /DOTATOC uptake greater than physiologic liver uptake by visual assessment. At least one lesion must be confirmed by conventional imaging (CT or MRI).
* For patients with measurable disease, the target lesion is one that either has never received external beam radiation or has been previously irradiated and has since demonstrated progression.
* For patients with no measurable disease (no meaurable target lesions), who have evaluable disease (bone disease, MIBG positive disease, liver metastases not detectable on MRI or CT), the disease must be seen on 68Ga-DOTATATE/DOTATOC PET/CT.
* No previous endogenous radiation with 177Lu-DOTATATE/TOC or 90Y-DOTATATE/TOC or 131I-MIBG within 12 months of most recent treatment.
* Age ≥ 18 months \< 20 years at the time of first study drug administration.
* Performance status as determined by Karnofsky ≥ 60 or Lansky Play Scale ≥ 60 at the time of study drug administration.

NOTE: Neurologic deficits in patients with brain metastases must have been stable for at least 7 days prior to study enrollment.

* Completion of validated Pediatric Quality of Life Questionnaire.
* Within seven (7) days of study drug administration, must have normal organ and bone marrow function as defined below:

Adequate Bone Marrow Function Defined as:

* Peripheral absolute neutrophil count (ANC) ≥ 1000/m3
* Platelet count ≥ 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
* Hemoglobin ≥ 8g/dL Organ Function Requirements
* AST(SGOT)\& ALT(SGPT) \<10X institutional upper limit of normal for age
* Total bilirubin \<3X ULN for age
* BUN \< 2X normal
* creatinine, Normal for age
* Glomerular filtration rate (GFR) only if creatinine \> normal for age
* Nuclear GFR or CrCl ≥ 80 ml/min/1.73m2
* Urinalysis No greater than 1+ hematuria or proteinuria
* The effects of 177Lu-DOTATATE on the developing human fetus are unknown. For this reason and because Class C agents are known to be teratogenic, all subjects capable of becoming pregnant must agree to practice a medically acceptable birth control measure (abstinence, birth control pills, intrauterine devices, vaginal diaphragm, vaginal sponge, or condom with spermicidal jelly) throughout the study and for eight months following the end of the last treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
* Parent's ability to understand and the willingness to sign a written informed consent document for children \< seven (7) years of age. Children ≥ seven (7) years of age will sign assent along with parental consent or will co-sign consent with parent in accordance with rules of the state in which treatment is received.

Exclusion Criteria

* Pregnant women are excluded from this study because 177Lu-DOTATATE is a Class C agent with potential teratogenic or abortifacient effects.
* Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 177Lu-DOTATATE, breastfeeding should be discontinued until 3 months after the last administration of study drug.
* Major surgery within 8 weeks of study drug administration.
* External beam radiation to both kidneys (scatter doses of \<500 cGy to a single kidney or radiation to \< 50% of a single kidney is acceptable).
* Prior PRRT with 90Y-DOTATOC (TATE) or 177Lu-DOTATOC (TATE) or 131I-MIBG for this malignancy within 12 months of first study dose.
* Another investigational drug within 8 weeks of study drug administration.
* Concurrent, malignant disease for which patient is on active therapy.
* Another significant medical, psychiatric, or surgical condition which is currently uncontrolled by treatment and which would likely affect the subject's ability to complete this protocol.
* Subjects who have received Sandostatin LAR or long-acting lanreotide in the past 28 days must be appropriately delayed. Subjects may be maintained on short acting octreotide during the time from last injection of long-acting somatostatin analogue until 8-24 hrs prior to injection of study drug.
* Known antibodies to Octreotide, Lanreotide, or DOTATATE or history of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTATATE.
* Uncontrolled illness including, but not limited to ongoing or active infection, uncontrolled diabetes mellitus, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hepatic cirrhosis or severe impairment, or psychiatric illness/social situations that would limit compliance with study requirements.
* Corticosteroids: Patients receiving corticosterods who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible. If used to modify immune adverse events related to prior therapy, ≥ 14 days must have elapsed since last dose of corticosteroid
* Patients who have received a prior solid organ transplantation are not eligible
* Patients will be excluded if they have a known allergy to any of the drugs used in the study
* Prior Therapy:
* Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive. At least 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea).
* Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or ANC counts): ≥ 7 days after the last dose of agent. Short-acting somatostatin analogue may be administered up to eight hours prior to infusion of study drug.
* Antibodies: ≥ 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to Grade ≤ 1.
* Hematopoietic growth factors: ≥ 14 days after the last dose of a long-acting growth factor (e.g. Peg-Filgrastim) or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair and the study-assigned Research Coordinator.
* Interleukins, Interferons and Cytokines (other than Hematopoietic Growth Factors): ≥ 21 days after the completion of interleukins, interferon or cytokines (other than Hematopoietic Growth Factors).
* Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion or boost infusion: ≥ 84 days after stem cell infusion
* Evidence of GVHD.
* Autologous stem cell infusion including boost infusion: ≥ 42 days; cellular therapy: ≥ 42 days after the completion of any type of cellular therapy (e.g. modified T cells, NK cells, dendritic cells, etc.).

Minimum Eligible Age

1 Year

Maximum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No